Toxicol Mech Methods 28:353360
The British National Formulary (BNF) does not list a specific interaction between semaglutide and bupropion, which provides reassurance regarding their concurrent use
Phase 3 clinical trials collectively referred to as the TRIUMPH programme are now underway internationally, evaluating retatrutide across broader populations including individuals with type 2 diabetes, obesity-related cardiovascular disease, and metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH)
Almost immediately, the FDA approved Sibutramin, a serotonin reuptake inhibitor that suppressed appetite
Semaglutide, a glucagon-like peptide-1 receptor agonist, has gained significant attention for its potential role in weight management and glycemic control